Jack Lawler

Mr. Lawler joined Chemomab in January of 2022 with more than 22 years of successful drug development experience. Prior to joining Chemomab, Mr. Lawler served on the Senior Leadership team as Vice President, Clinical Operations and Data Management at Goldfinch Bio. Prior to Goldfinch Bio, Mr. Lawler has held a series of drug development positions at several small and mid-size biotechnology companies and has participated in the drug development for eight approved pharmaceutical products at Teva (Cephalon), Trevena, Shire (Viropharma) and Egalet. Mr. Lawler earned a Bachelor of Science in Business Management from Rosemont College.